The global anthrax vaccines market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market can be attributed to the increasing demand for anthrax vaccines in various regions across the globe. The increase in demand for anthrax vaccines is due to the rise in number of cases and outbreaks of anthrax infections globally. In addition, there are various factors such as increased awareness about prevention and treatment methods, which are driving the growth of this market.
The live vaccine segment accounted for more than half (55%) share in 2018 and is expected to maintain its dominance throughout the forecast period owing to its efficacy against all types of strains and species that cause anthrax infection. Cell free PA vaccine segment accounted for less than 10% share in 2018 but is expected to grow at a CAGR higher than live vaccine segment during 2020-2030 owing to its safety profile with no risk of transmission or mutation into other strains or species that cause infection with no risk associated with immunization process as it does not contain any living organism or virus particles which may lead adverse effects on human health like fever, headache etc,.
- The global Anthrax Vaccines market is expected to grow at a CAGR of 5.5% during the forecast period, 2018-2025.
- The global Anthrax Vaccines market is driven by factors such as increasing prevalence of infectious diseases and growing demand for vaccines in emerging economies such as China and India.
- Increasing awareness about the benefits of vaccination among people in developing countries is also driving the growth of this market.
- Increasing government initiatives to promote vaccination programs are also driving the growth of this market.
- Lack of awareness about vaccine safety among people in developing countries is restraining the growth of this market.
Industry Growth Insights published a new data on “Anthrax Vaccines Market”. The research report is titled “Anthrax Vaccines Market research by Types (Live Vaccines, Cell free PA Vaccines), By Applications (Human Use, Animal Use), By Players/Companies Emergent BioSolutions, Merial, Merck, Zoetis, Bayer Sanidad Animal, Colorado Serum, PharmAthene, Tiankang, Biogénesis-Bago, CAVAC, Rosenbusch, Agrovet, Vecol, CVCRI, IVPM, Prondil, CDV, Indian Immunologicals, Botswana Vaccine Institute, Ceva Santé Animale, Intervac, JOVAC”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Anthrax Vaccines Market Research Report
By Type
Live Vaccines, Cell free PA Vaccines
By Application
Human Use, Animal Use
By Companies
Emergent BioSolutions, Merial, Merck, Zoetis, Bayer Sanidad Animal, Colorado Serum, PharmAthene, Tiankang, Biogénesis-Bago, CAVAC, Rosenbusch, Agrovet, Vecol, CVCRI, IVPM, Prondil, CDV, Indian Immunologicals, Botswana Vaccine Institute, Ceva Santé Animale, Intervac, JOVAC
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global Anthrax Vaccines Market Report Segments:
The global Anthrax Vaccines market is segmented on the basis of:
Types
Live Vaccines, Cell free PA Vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Human Use, Animal Use
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Emergent BioSolutions
- Merial
- Merck
- Zoetis
- Bayer Sanidad Animal
- Colorado Serum
- PharmAthene
- Tiankang
- Biogénesis-Bago
- CAVAC
- Rosenbusch
- Agrovet
- Vecol
- CVCRI
- IVPM
- Prondil
- CDV
- Indian Immunologicals
- Botswana Vaccine Institute
- Ceva Santé Animale
- Intervac
- JOVAC
Highlights of The Anthrax Vaccines Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Live Vaccines
- Cell free PA Vaccines
- By Application:
- Human Use
- Animal Use
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Anthrax Vaccines Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Anthrax vaccines are a type of vaccine that helps protect people from anthrax. Anthrax is a serious and potentially deadly infection caused by the bacterium Bacillus anthracis. Anthrax vaccines help prevent anthrax infections by helping to create immunity to the disease.
Some of the major companies in the anthrax vaccines market are Emergent BioSolutions, Merial, Merck, Zoetis, Bayer Sanidad Animal, Colorado Serum, PharmAthene, Tiankang, BiogƒÂ©nesis-Bago, CAVAC, Rosenbusch, Agrovet, Vecol, CVCRI, IVPM, Prondil, CDV, Indian Immunologicals, Botswana Vaccine Institute, Ceva SantƒÂ© Animale, Intervac, JOVAC.
The anthrax vaccines market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Anthrax Vaccines Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Anthrax Vaccines Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Anthrax Vaccines Market - Supply Chain
4.5. Global Anthrax Vaccines Market Forecast
4.5.1. Anthrax Vaccines Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Anthrax Vaccines Market Size (000 Units) and Y-o-Y Growth
4.5.3. Anthrax Vaccines Market Absolute $ Opportunity
5. Global Anthrax Vaccines Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Anthrax Vaccines Market Size and Volume Forecast by Type
5.3.1. Live Vaccines
5.3.2. Cell free PA Vaccines
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Anthrax Vaccines Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Anthrax Vaccines Market Size and Volume Forecast by Application
6.3.1. Human Use
6.3.2. Animal Use
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Anthrax Vaccines Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Anthrax Vaccines Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Anthrax Vaccines Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Anthrax Vaccines Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Anthrax Vaccines Demand Share Forecast, 2019-2026
9. North America Anthrax Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Anthrax Vaccines Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Anthrax Vaccines Market Size and Volume Forecast by Application
9.4.1. Human Use
9.4.2. Animal Use
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Anthrax Vaccines Market Size and Volume Forecast by Type
9.7.1. Live Vaccines
9.7.2. Cell free PA Vaccines
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Anthrax Vaccines Demand Share Forecast, 2019-2026
10. Latin America Anthrax Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Anthrax Vaccines Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Anthrax Vaccines Market Size and Volume Forecast by Application
10.4.1. Human Use
10.4.2. Animal Use
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Anthrax Vaccines Market Size and Volume Forecast by Type
10.7.1. Live Vaccines
10.7.2. Cell free PA Vaccines
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Anthrax Vaccines Demand Share Forecast, 2019-2026
11. Europe Anthrax Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Anthrax Vaccines Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Anthrax Vaccines Market Size and Volume Forecast by Application
11.4.1. Human Use
11.4.2. Animal Use
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Anthrax Vaccines Market Size and Volume Forecast by Type
11.7.1. Live Vaccines
11.7.2. Cell free PA Vaccines
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
1.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Anthrax Vaccines Demand Share, 2019-2026
12. Asia Pacific Anthrax Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Anthrax Vaccines Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Anthrax Vaccines Market Size and Volume Forecast by Application
12.4.1. Human Use
12.4.2. Animal Use
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Anthrax Vaccines Market Size and Volume Forecast by Type
12.7.1. Live Vaccines
12.7.2. Cell free PA Vaccines
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Anthrax Vaccines Demand Share, 2019-2026
13. Middle East & Africa Anthrax Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Anthrax Vaccines Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Anthrax Vaccines Market Size and Volume Forecast by Application
13.4.1. Human Use
13.4.2. Animal Use
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Anthrax Vaccines Market Size and Volume Forecast by Type
13.7.1. Live Vaccines
13.7.2. Cell free PA Vaccines
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Anthrax Vaccines Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Anthrax Vaccines Market: Market Share Analysis
14.2. Anthrax Vaccines Distributors and Customers
14.3. Anthrax Vaccines Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Emergent BioSolutions
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merial
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Merck
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Zoetis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Bayer Sanidad Animal
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Colorado Serum
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. PharmAthene
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Tiankang
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Biogénesis-Bago
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. CAVAC
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Rosenbusch
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Agrovet
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. Vecol
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. CVCRI
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. IVPM
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Prondil
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. CDV
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Indian Immunologicals
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Botswana Vaccine Institute
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Ceva Santé Animale
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
